Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$24.07
+3.2%
$23.04
$20.36
$82.41
$2.22B0.931.84 million shs846,771 shs
Neurogene Inc. stock logo
NGNE
Neurogene
$20.28
+4.0%
$17.87
$6.88
$74.49
$289.23M1.51250,420 shs48,282 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$2.44
+4.3%
$2.51
$1.05
$3.31
$523.77M0.972.92 million shs1.88 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
-2.43%+2.78%+2.55%-14.01%-64.63%
Neurogene Inc. stock logo
NGNE
Neurogene
-2.72%+30.43%-10.67%+165.67%-42.87%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-2.50%+1.30%-17.61%+107.08%+13.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
4.8124 of 5 stars
4.33.00.05.02.00.02.5
Neurogene Inc. stock logo
NGNE
Neurogene
3.5928 of 5 stars
4.43.00.00.01.81.71.3
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.1524 of 5 stars
4.51.00.00.02.33.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
2.60
Moderate Buy$47.9499.19% Upside
Neurogene Inc. stock logo
NGNE
Neurogene
2.75
Moderate Buy$46.17127.65% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$8.20236.07% Upside

Current Analyst Ratings Breakdown

Latest ACHC, NGNE, and TSHA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/17/2025
Neurogene Inc. stock logo
NGNE
Neurogene
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
6/12/2025
Neurogene Inc. stock logo
NGNE
Neurogene
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.00
6/10/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/3/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $11.00
6/2/2025
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/2/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $8.00
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $6.00
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $9.00
5/20/2025
Neurogene Inc. stock logo
NGNE
Neurogene
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$3.15B0.70$5.08 per share4.74$33.09 per share0.73
Neurogene Inc. stock logo
NGNE
Neurogene
$925K312.68N/AN/A$20.89 per share0.97
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$8.33M62.88N/AN/A$0.35 per share6.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$255.61M$2.0311.867.104.445.94%8.72%4.46%7/30/2025 (Estimated)
Neurogene Inc. stock logo
NGNE
Neurogene
-$75.14M-$4.35N/AN/AN/AN/A-36.16%-32.51%8/8/2025 (Estimated)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$89.30M-$0.34N/AN/AN/A-1,201.08%-104.93%-50.09%8/11/2025 (Estimated)

Latest ACHC, NGNE, and TSHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$0.70N/AN/AN/A$839.59 millionN/A
5/15/2025Q1 2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million
5/12/2025Q1 2025
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$0.35$0.40+$0.05$0.09$769.90 million$770.51 million
5/9/2025Q1 2025
Neurogene Inc. stock logo
NGNE
Neurogene
-$1.05-$1.08-$0.03-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/AN/AN/AN/AN/A
Neurogene Inc. stock logo
NGNE
Neurogene
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
0.72
1.35
1.35
Neurogene Inc. stock logo
NGNE
Neurogene
N/A
21.03
21.03
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.77
5.35
5.35

Institutional Ownership

CompanyInstitutional Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/A
Neurogene Inc. stock logo
NGNE
Neurogene
52.37%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
2.00%
Neurogene Inc. stock logo
NGNE
Neurogene
11.64%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
25,50092.12 million90.28 millionOptionable
Neurogene Inc. stock logo
NGNE
Neurogene
9014.26 million12.85 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
180214.66 million206.55 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acadia Healthcare stock logo

Acadia Healthcare NASDAQ:ACHC

$24.07 +0.75 (+3.22%)
As of 03:22 PM Eastern

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

Neurogene stock logo

Neurogene NASDAQ:NGNE

$20.28 +0.78 (+4.00%)
As of 03:16 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$2.44 +0.10 (+4.27%)
As of 03:22 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.